Chiusura precedente | 0,4790 |
Aperto | 0,4500 |
Denaro | 0,3109 x 200 |
Domanda | 0,5720 x 200 |
Min-Max giorno | 0,4350 - 0,4500 |
Intervallo di 52 settimane | 0,1540 - 9,4900 |
Volume | |
Media Volume | 221.038 |
Capitalizzazione | 7,809M |
Beta (mensile su 5 anni) | 1,83 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,1900 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
KUALA LUMPUR, Malaysia, July 24, 2023 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BioNexus” or the “Company”) (Nasdaq: BGLC), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liquid biopsy tests for early diagnosis and personalized health management, today announced the closing of an underwritten public offering (the “Offering”) of 1,437,500 shares of common stock, including 187,500 share
KUALA LUMPUR, Malaysia, July 20, 2023 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BioNexus” or the “Company”), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liquid biopsy tests for early diagnosis and personalized health management, today announced the pricing of its Public Offering (the “Offering”) of 1,250,000 shares of common stock at a price of $4.00 per share for total gross proce